Evidence map›Paper›PMID 35716991›Full record

ArticleVascular pharmacology2022

Telehealth: A winning weapon to face the COVID-19 outbreak for patients with pulmonary arterial hypertension.

Giovanna Manzi, Silvia Papa, Marco Valerio Mariani, Gianmarco Scoccia, Domenico Filomena, Claudia Malerba, Francesca Ileana Adamo, Annalisa Caputo, Claudio De Lazzari, Beatrice De Lazzari and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. The next viral pandemic-where do we stand?Folia microbiologica · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Giovanna ManziDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: giovannamanzi91@gmail.com.
Silvia PapaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: silviapapa83@gmail.com.
Marco Valerio MarianiDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: marcoval.mariani@gmail.com.
Gianmarco ScocciaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: gianmarcoscoccia@gmail.com.
Domenico FilomenaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: domenico.filomena@uniroma1.it.
Claudia MalerbaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: claudiamalerba4@gmail.com.
Francesca Ileana AdamoDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: francescaileana.adamo@uniroma1.it.
Annalisa CaputoDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: annalisa.caputo@uniroma1.it.
Claudio De LazzariNational Research Council, Institute of Clinical Physiology (IFC-CNR), Rome, Italy. Electronic address: claudio.delazzari@ifc.cnr.it.
Beatrice De LazzariUniversità degli Studi di Roma "Foro Italico", P.za Lauro De Bosis, 15, 00135 Rome, Italy. Electronic address: beatrice.delazzari@gmail.com.
Nadia CedroneUnità di Medicina Interna, Ospedale S. Pertini, Rome, Italy. Electronic address: nadiacedrone@gmail.com.
Rosalinda MadonnaCardiology Unit, Department of Surgical, Medical and Molecular Pathology and of Critical Sciences, University of Pisa - UNIPI, Pisa, Italy. Electronic address: rosalinda.madonna@unipi.it.
Tommaso RecchioniDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: recchioni.1739479@studenti.uniroma1.it.
Giorgia SerinoDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: giorgia.serino@uniroma1.it.
Carmine Dario VizzaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: dario.vizza@uniroma1.it.
Roberto BadagliaccaDepartment of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy. Electronic address: roberto.badagliacca@uniroma1.it.
Sapienza University of Rome · ITPoliclinico Umberto I · ITForo Italico University of Rome · ITNational Research Council · ITOspedale Sandro Pertini · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 pandemic severely affected national health systems, altering the modality and the type of care of patients with acute and chronic diseases. To minimize the risk of exposure to SARS-CoV2 for patients and health professionals, face-to-face visits were cancelled or postponed and the use of telemedicine was strongly encouraged. This reorganization involved especially patients with rare diseases needing periodic comprehensive assessment, such as pulmonary arterial hypertension (PAH). MAIN BODY: The paper reports a proposal of strategy adopted for patients followed at our PAH center in Rome, where patients management was diversified based on clinical risk according to the European Society of Cardiology/European Respiratory Society PH guidelines-derived score and the REVEAL 2.0 score. A close monitoring and support of these patients were made possible by policy changes reducing barriers to telehealth access and promoting the use of telemedicine. Synchronous/asynchronous modalities and remote monitoring were used to collect and transfer medical data in order to guide physicians in therapeutic-decision making. Conversely, the use of implantable monitors providing hemodynamic information and echocardiography-mobile devices wirelessly connecting was limited by the poor experience existing in this setting. Large surveys and clinical trials are welcome to test the potential benefit of the optimal balance between traditional PAH management and telemedicine opportunities.

conclusionItaly was found unprepared to manage the dramatic effects caused by COVID-19 on healthcare systems. In this emergency situation telemedicine represented a promising tool especially in rare diseases as PAH, but was limited by its scattered availability and legal and ethical issues. Cohesive partnership of health care providers with regional public health officials is needed to prioritize PAH patients for telemedicine by dedicated tools.

Indexed as

COVID-19Pulmonary Arterial HypertensionTelemedicineHumansPandemicsRare DiseasesRNA, ViralSARS-CoV-2RNA, ViralCOVID-19Pulmonary arterial hypertensionTelecardiologyTelemedicine

Identifiers

PMID35716991
PMCPMC9212864
OpenAlexW4282975964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.